Original Article

Evaluation of the Efficacy and Safety of Outpatient Parenteral Antimicrobial Therapy for Infections With Methicillin-sensitive Staphylococcus aureus

Authors: Melissa Wynn, MD, Joseph R. Dalovisio, MD, Alan D. Tice, MD, Xiaozhang Jiang, MS

Abstract

Objectives: As increasing numbers of patients are being treated with outpatient parenteral antimicrobial therapy (OPAT), it becomes ever more important to ascertain the risks and benefits of such treatment for patients.


Methods: We conducted a retrospective analysis of 1,515 patients with methicillin-sensitiveStaphylococcus aureus infections who were treated with outpatient parenteral antimicrobial monotherapy. All patients were included in the adverse drug reaction analysis; 1,252 were evaluable for purposes of evaluating treatment efficacy.


Results: The six antibiotics most frequently used in this study (ceftriaxone, cefazolin, vancomycin, oxacillin, nafcillin, and clindamycin) appeared to be equivalent in achieving the desired efficacy outcome.


Conclusions: Vancomycin was associated with a significantly greater number of side effects than was ceftriaxone, cefazolin, or oxacillin, and nafcillin was associated with a significantly greater number of adverse events than ceftriaxone.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Williams DN, Rehm SJ, Tice AD, et al. Practice guidelines for community-based parenteral anti-infective therapy: ISDA Practice Guidelines Committee. Clin Infect Dis 1997;25:787–801.
 
2. Bernard L, El-hajj, Pron B, et al. Outpatient parenteral antimicrobial therapy (OPAT) for the treatment of osteomyelitis: evaluation of efficacy, tolerance and cost. J Clin Pharm Ther 2001;26:445–451.
 
3. Deery HG II. Outpatient parenteral anti-infective therapy for skin and soft-tissue infections. Infect Dis Clin North Am 1998;12:935–949.
 
4. Nathwani D, Tice A. Ambulatory antimicrobial use: the value of an outcomes registry. J Antimicrob Chemother 2002;49:149–154.
 
5. Tice AD, Rehm SJ, Dalovisio JR, et al. Practice guidelines for outpatient parenteral antimicrobial therapy. Clin Infect Dis 2004;38:1651–1672.
 
6. Tice AD, Schleis TG, Nolet B, et al. Outcomes registry for outpatient IV antimicrobial therapy.Infusion 2000;6:27–35.
 
7. Parsonnet J, Deresiewicz RL. Staphylococcal infections, in Braunwald E, Fauci AS, Kasper DL, et al (eds): Harrison's Principles of Internal Medicine. 15th ed. New York: McGraw Hill, 2001, pp 889–901.
 
8. Martinelli LP, Tice A, Hoaglund P. Outpatient parenteral antimicrobial therapy (OPAT): safety, efficacy and outcomes. Presented at the 38th Annual Meeting of the Infectious Diseases Society of America, New Orleans, LA, September 7 to 10, 2000.
 
9. Tice A, Seibold G, Martinelli L. Adverse effects from intravenous antibiotics with OPAT. Presented at the 40th Annual Meeting of the Infectious Diseases Society of America, Chicago, L, October 24 to 27, 2002. Poster No. 59.